Point72 Hong Kong LTD Ironwood Pharmaceuticals Inc Transaction History

Point72 Hong Kong LTD

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$10.14 - $12.38 $344,628 - $420,759	33,987 New	33,987 $352,000
Q2 2022 Aug 15, 2022	SELL	$11.05 - $12.72 $50,167 - $57,748	-4,540 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$10.61 - $12.88 $174,948 - $212,378	-16,489 Reduced 78.41%	4,540 $57,000
Q4 2021 Feb 14, 2022	BUY	$10.86 - $13.95 $192,308 - $247,026	17,708 Added 533.21%	21,029 $245,000
Q3 2021 Nov 15, 2021	BUY	$11.92 - $13.92 $39,586 - $46,228	3,321 New	3,321 $43,000
Q2 2020 Aug 14, 2020	SELL	$9.14 - $11.97 $50,781 - $66,505	-5,556 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$8.58 - $14.01 $47,670 - $77,839	5,556 New	5,556 $56,000
Q2 2019 Aug 14, 2019	SELL	$9.8 - $12.89 $3,312 - $4,356	-338 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$8.27 - $12.73 $611 - $942	74 Added 28.03%	338 $5,000
Q4 2018 Feb 14, 2019	BUY	$7.8 - $16.13 $522 - $1,080	67 Added 34.01%	264 $3,000
Q3 2018 Nov 14, 2018	BUY	$14.31 - $17.65 $2,819 - $3,477	197 New	197 $4,000

238

162M

11.2M

9.1K

Ticker IRWD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 153,231,008
Market Cap $530M
Description
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZE...

Get notified when there are updates to the investment portfolio of Point72 Hong Kong LTD, based on Form 13F filings with the SEC.

Stay updated on Point72 Hong Kong LTD with notifications on news.